+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Biperiden Market by Formulation, Type, Indication, Route Of Administration, Patient Age Group, End-User - Global Forecast to 2030- Product Image
Biperiden Market by Formulation, Type, Indication, Route Of Administration, Patient Age Group, End-User - Global Forecast to 2030- Product Image
Sale

Biperiden Market by Formulation, Type, Indication, Route Of Administration, Patient Age Group, End-User - Global Forecast to 2030

  • PDF Icon

    Report

  • 188 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6082731
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Biperiden Market grew from USD 384.70 million in 2024 to USD 407.10 million in 2025. It is expected to continue growing at a CAGR of 5.71%, reaching USD 537.08 million by 2030.

Revolutionizing Neurological Treatment with Biperiden

The burden of movement disorders and drug-induced motor complications has propelled anticholinergic therapies into the spotlight, with Biperiden emerging as a cornerstone treatment. Its mechanism of action addresses acetylcholine-dopamine imbalances, offering clinicians a potent tool to manage extrapyramidal symptoms and Parkinsonian manifestations. As health systems worldwide grapple with aging populations and prolonged pharmacotherapy, Biperiden’s profile assumes ever greater strategic importance for formulary committees, therapeutic decision-makers, and commercial strategists.

This executive summary distills a rigorous market analysis designed to illuminate the critical forces shaping Biperiden’s trajectory. By examining regulatory shifts, tariff impacts, segmentation dynamics, and regional variations, it equips stakeholders with the clarity needed to navigate complexity. The following sections deliver a holistic perspective rooted in validated data sources and expert insights, empowering you to align product development, market access, and go-to-market planning with emerging opportunities.

Emerging Dynamics Reshaping Biperiden’s Future

Over the past decade, the Biperiden landscape has experienced paradigm-altering dynamics that extend well beyond traditional product lifecycles. Patent expirations have unlocked a wave of generic entrants, compelling innovators to differentiate with novel formulations and delivery mechanisms. Concurrently, regulatory agencies have introduced streamlined pathways for anticholinergic approvals, accelerating time to market for both originators and biosimilars alike.

Technological advancements in drug delivery and digital adherence tools have further reshaped patient engagement models, creating avenues for value-based contracting and performance-linked reimbursement. In parallel, expanding clinical research into combination therapies has broadened therapeutic protocols, with Biperiden frequently paired alongside dopaminergic agents to optimize symptom control. As healthcare providers and payers recalibrate treatment algorithms, these shifts collectively redefine competitive positioning, driving a more dynamic ecosystem that rewards agility, innovation, and evidence-backed differentiation.

Unpacking the 2025 US Tariffs Impact on Biperiden Supply Chains

The implementation of new tariff measures in 2025 has introduced a material inflection point for Biperiden supply chains and cost structures. Import duties on active pharmaceutical ingredients have elevated input costs, prompting manufacturers to reevaluate sourcing strategies and production footprints. For those dependent on offshore API suppliers, tariff-related expenses have necessitated deliberate shifts toward regional manufacturing hubs and strategic inventory buffers to mitigate pricing volatility.

Importers and distributors now face recalibrated margin pressures, which have spurred a wave of cost-containment initiatives across Contract Manufacturing Organizations and distribution networks. Meanwhile, commercial teams are engaging more proactively with pricing authorities to secure reimbursement adjustments that reflect elevated manufacturing outlays. In this evolving environment, companies that adopt resilient supply chain frameworks and negotiate forward-looking supply agreements will enjoy a competitive edge, while those slow to adapt risk margin erosion and market share decline.

Deep Dive into Biperiden Market Segmentation Patterns

Analysis by formulation reveals two primary formats: injectable and oral, with the oral variant further delineated into 2 mg and 4 mg strengths to meet dose-titration requirements. When evaluating product ownership, branded formulations benefit from established physician trust whereas generic equivalents leverage cost competitiveness to drive high-volume uptake. Clinical application splits along indication lines between management of drug-induced extrapyramidal reactions and treatment of Parkinson’s disease, each demanding tailored dosing profiles.

Delivery considerations encompass both oral administration, favored for outpatient settings, and parenteral routes that address acute care scenarios. Demographically, adult patients historically represent the bulk of usage, yet the geriatric cohort is experiencing rapid growth due to longer life expectancy and chronic therapy needs. End-user channels span outpatient clinics where maintenance regimens prevail, home care environments that prioritize convenience and adherence, and hospital settings managing acute presentations. These intersecting segmentation dimensions reveal nuanced opportunity spaces where targeted strategies can yield disproportionate returns.

Navigating Regional Variations Affecting Biperiden Demand

Regional demand patterns for Biperiden reflect diverse healthcare infrastructures and policy environments. In the Americas, reimbursement frameworks and payer negotiations drive access decisions, with managed care plans emphasizing formulary optimization and cost-effectiveness metrics. Meanwhile, emerging markets within the region present growth prospects anchored in urbanization and expanding neurology services.

Within Europe, Middle East & Africa, heterogeneous regulatory regimes and variable healthcare funding models create a mosaic of market entry considerations. Western European nations pursue stringent value-based assessments, while Gulf Cooperation Council countries prioritize rapid approval pathways. Africa’s market remains nascent but shows early signs of commercialization interest as neurological disease awareness rises. In Asia-Pacific, robust generics manufacturing, evolving intellectual property landscapes, and public sector procurement programs shape competitive dynamics. Variations in patient affordability, local production capabilities, and distribution infrastructure underscore the need for region-specific strategies that align regulatory affairs, market access, and sales execution.

Insights into Leading Companies Driving Biperiden Innovation

The competitive arena features both global generic manufacturers and specialty pharmaceutical companies. Leading players are investing in expanded production capacity, fortified by strategic acquisitions that secure API supply. Some innovators concentrate on life-cycle management through improved-release oral formulations that enhance patient adherence while extending patent protection. Others prioritize partnerships with clinical research organizations to generate real-world evidence supporting off-label and adjunctive uses.

Meanwhile, contract development and manufacturing organizations are carving out niche expertise in scalable antibody-drug conjugate platforms, signaling potential for novel hybrid therapies. Collaborative ventures between pharmaceutical firms and technology providers are emerging to integrate digital adherence monitoring with remote patient management-initiatives that promise to redefine the standard of care. Companies that harness these cross-sector synergies will strengthen their competitive moats and establish leadership in the expanding movement disorders segment.

Strategic Actions for Industry Leaders to Capitalize on Biperiden Trends

Leaders in the Biperiden ecosystem should consider diversifying API sourcing across multiple geographies to buffer against tariff-related disruptions and safeguard supply continuity. Investing in differentiated oral controlled-release formulations can unlock premium positioning within both branded and generic segments, while strategic collaborations with payers can cement value-based contracts tied to patient outcomes. Embracing digital adherence platforms will enhance real-world data capture and support pricing negotiations grounded in demonstrated therapeutic benefit.

Industry executives should also pursue targeted acquisitions of regional contract manufacturers to accelerate market entry in high-growth territories, and establish center-of-excellence partnerships with academic institutions to pioneer novel combination therapies. By integrating these approaches into a cohesive market access and commercialization roadmap, organizations can convert emerging trends into sustainable competitive advantages.

Rigorous Approach Underpinning the Biperiden Market Study

This study leveraged a multi-tiered research design combining comprehensive secondary research with primary interviews of neurologists, formulary decision-makers, and supply chain experts. Data sources encompassed regulatory filings, health technology assessment reports, clinical trial registries, and proprietary transaction databases. Rigorous data triangulation ensured consistency across quantitative metrics, while qualitative insights were validated through expert roundtables.

The segmentation framework was developed by mapping product characteristics against clinical use cases and patient demographics. Regional analysis integrated policy reviews with on-the-ground market intelligence. Competitive profiling employed a blend of financial disclosures, patent analyses, and partnership announcements. This methodological rigor underpins the credibility of the findings and the actionable insights derived herein.

Synthesizing Key Takeaways on Biperiden Market Evolution

In summary, Biperiden’s market is undergoing significant transformation driven by regulatory reforms, tariff-induced supply chain realignments, and intensified segmentation strategies. Regional heterogeneity underscores the imperative for localized market access and pricing models, while competitive dynamics favor companies that can marry product innovation with strategic network expansion. The integration of digital health tools and real-world evidence is poised to elevate Biperiden from a legacy anticholinergic to a platform for value-based neurology care.

By internalizing the insights and recommendations presented in this summary, stakeholders can anticipate pivotal inflection points and position their organizations to capture emerging opportunities. The evolving landscape calls for proactive leadership, adaptive strategies, and sustained investments in both product development and market infrastructure.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Formulation
    • Injectable
    • Oral
      • 2 mg
      • 4 mg
  • Type
    • Branded
    • Generic
  • Indication
    • Extrapyramidal Symptoms
    • Parkinson's Disease
  • Route Of Administration
    • Oral
    • Parenteral
  • Patient Age Group
    • Adults
    • Geriatric
  • End-User
    • Clinics
    • Home Care
    • Hospitals
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Teva Pharmaceutical Industries Ltd.
  • Sandoz International GmbH
  • Viatris Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Lupin Limited
  • Janssen-Cilag International NV
  • Aurobindo Pharma Limited
  • Apotex Inc.
  • Glenmark Pharmaceuticals Limited

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Biperiden Market, by Formulation
8.1. Introduction
8.2. Injectable
8.3. Oral
8.3.1. 2 mg
8.3.2. 4 mg
9. Biperiden Market, by Type
9.1. Introduction
9.2. Branded
9.3. Generic
10. Biperiden Market, by Indication
10.1. Introduction
10.2. Extrapyramidal Symptoms
10.3. Parkinson's Disease
11. Biperiden Market, by Route Of Administration
11.1. Introduction
11.2. Oral
11.3. Parenteral
12. Biperiden Market, by Patient Age Group
12.1. Introduction
12.2. Adults
12.3. Geriatric
13. Biperiden Market, by End-User
13.1. Introduction
13.2. Clinics
13.3. Home Care
13.4. Hospitals
14. Americas Biperiden Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Biperiden Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Biperiden Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Teva Pharmaceutical Industries Ltd.
17.3.2. Sandoz International GmbH
17.3.3. Viatris Inc.
17.3.4. Sun Pharmaceutical Industries Ltd.
17.3.5. Dr. Reddy's Laboratories Ltd.
17.3.6. Lupin Limited
17.3.7. Janssen-Cilag International NV
17.3.8. Aurobindo Pharma Limited
17.3.9. Apotex Inc.
17.3.10. Glenmark Pharmaceuticals Limited
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. BIPERIDEN MARKET MULTI-CURRENCY
FIGURE 2. BIPERIDEN MARKET MULTI-LANGUAGE
FIGURE 3. BIPERIDEN MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BIPERIDEN MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BIPERIDEN MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BIPERIDEN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BIPERIDEN MARKET SIZE, BY FORMULATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BIPERIDEN MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BIPERIDEN MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BIPERIDEN MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BIPERIDEN MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BIPERIDEN MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BIPERIDEN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BIPERIDEN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL BIPERIDEN MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 16. GLOBAL BIPERIDEN MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL BIPERIDEN MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 18. GLOBAL BIPERIDEN MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS BIPERIDEN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS BIPERIDEN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES BIPERIDEN MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES BIPERIDEN MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA BIPERIDEN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA BIPERIDEN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC BIPERIDEN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC BIPERIDEN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. BIPERIDEN MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. BIPERIDEN MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BIPERIDEN MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BIPERIDEN MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BIPERIDEN MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BIPERIDEN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BIPERIDEN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BIPERIDEN MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BIPERIDEN MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BIPERIDEN MARKET SIZE, BY 2 MG, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BIPERIDEN MARKET SIZE, BY 4 MG, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BIPERIDEN MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BIPERIDEN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BIPERIDEN MARKET SIZE, BY BRANDED, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BIPERIDEN MARKET SIZE, BY GENERIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BIPERIDEN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BIPERIDEN MARKET SIZE, BY EXTRAPYRAMIDAL SYMPTOMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BIPERIDEN MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BIPERIDEN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BIPERIDEN MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BIPERIDEN MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BIPERIDEN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BIPERIDEN MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BIPERIDEN MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BIPERIDEN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BIPERIDEN MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BIPERIDEN MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BIPERIDEN MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS BIPERIDEN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS BIPERIDEN MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS BIPERIDEN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS BIPERIDEN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS BIPERIDEN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS BIPERIDEN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS BIPERIDEN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS BIPERIDEN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 36. UNITED STATES BIPERIDEN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 37. UNITED STATES BIPERIDEN MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 38. UNITED STATES BIPERIDEN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 39. UNITED STATES BIPERIDEN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 40. UNITED STATES BIPERIDEN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 41. UNITED STATES BIPERIDEN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 42. UNITED STATES BIPERIDEN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES BIPERIDEN MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 44. CANADA BIPERIDEN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 45. CANADA BIPERIDEN MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 46. CANADA BIPERIDEN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 47. CANADA BIPERIDEN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 48. CANADA BIPERIDEN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 49. CANADA BIPERIDEN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 50. CANADA BIPERIDEN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 51. MEXICO BIPERIDEN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 52. MEXICO BIPERIDEN MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 53. MEXICO BIPERIDEN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 54. MEXICO BIPERIDEN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 55. MEXICO BIPERIDEN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 56. MEXICO BIPERIDEN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 57. MEXICO BIPERIDEN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 58. BRAZIL BIPERIDEN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 59. BRAZIL BIPERIDEN MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 60. BRAZIL BIPERIDEN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 61. BRAZIL BIPERIDEN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 62. BRAZIL BIPERIDEN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 63. BRAZIL BIPERIDEN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 64. BRAZIL BIPERIDEN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 65. ARGENTINA BIPERIDEN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 66. ARGENTINA BIPERIDEN MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 67. ARGENTINA BIPERIDEN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 68. ARGENTINA BIPERIDEN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 69. ARGENTINA BIPERIDEN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 70. ARGENTINA BIPERIDEN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 71. ARGENTINA BIPERIDEN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 72. EUROPE, MIDDLE EAST & AFRICA BIPERIDEN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 73. EUROPE, MIDDLE EAST & AFRICA BIPERIDEN MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 74. EUROPE, MIDDLE EAST & AFRICA BIPERIDEN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 75. EUROPE, MIDDLE EAST & AFRICA BIPERIDEN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 76. EUROPE, MIDDLE EAST & AFRICA BIPERIDEN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 77. EUROPE, MIDDLE EAST & AFRICA BIPERIDEN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA BIPERIDEN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA BIPERIDEN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 80. UNITED KINGDOM BIPERIDEN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 81. UNITED KINGDOM BIPERIDEN MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 82. UNITED KINGDOM BIPERIDEN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 83. UNITED KINGDOM BIPERIDEN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 84. UNITED KINGDOM BIPERIDEN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 85. UNITED KINGDOM BIPERIDEN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 86. UNITED KINGDOM BIPERIDEN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 87. GERMANY BIPERIDEN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 88. GERMANY BIPERIDEN MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 89. GERMANY BIPERIDEN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 90. GERMANY BIPERIDEN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 91. GERMANY BIPERIDEN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 92. GERMANY BIPERIDEN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 93. GERMANY BIPERIDEN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 94. FRANCE BIPERIDEN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 95. FRANCE BIPERIDEN MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 96. FRANCE BIPERIDEN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 97. FRANCE BIPERIDEN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 98. FRANCE BIPERIDEN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 99. FRANCE BIPERIDEN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 100. FRANCE BIPERIDEN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 101. RUSSIA BIPERIDEN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 102. RUSSIA BIPERIDEN MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 103. RUSSIA BIPERIDEN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 104. RUSSIA BIPERIDEN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 105. RUSSIA BIPERIDEN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 106. RUSSIA BIPERIDEN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 107. RUSSIA BIPERIDEN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 108. ITALY BIPERIDEN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 109. ITALY BIPERIDEN MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 110. ITALY BIPERIDEN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 111. ITALY BIPERIDEN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 112. ITALY BIPERIDEN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 113. ITALY BIPERIDEN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 114. ITALY BIPERIDEN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 115. SPAIN BIPERIDEN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 116. SPAIN BIPERIDEN MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 117. SPAIN BIPERIDEN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 118. SPAIN BIPERIDEN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 119. SPAIN BIPERIDEN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 120. SPAIN BIPERIDEN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 121. SPAIN BIPERIDEN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 122. UNITED ARAB EMIRATES BIPERIDEN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 123. UNITED ARAB EMIRATES BIPERIDEN MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 124. UNITED ARAB EMIRATES BIPERIDEN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 125. UNITED ARAB EMIRATES BIPERIDEN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 126. UNITED ARAB EMIRATES BIPERIDEN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 127. UNITED ARAB EMIRATES BIPERIDEN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 128. UNITED ARAB EMIRATES BIPERIDEN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 129. SAUDI ARABIA BIPERIDEN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 130. SAUDI ARABIA BIPERIDEN MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 131. SAUDI ARABIA BIPERIDEN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 132. SAUDI ARABIA BIPERIDEN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 133. SAUDI ARABIA BIPERIDEN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 134. SAUDI ARABIA BIPERIDEN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 135. SAUDI ARABIA BIPERIDEN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 136. SOUTH AFRICA BIPERIDEN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 137. SOUTH AFRICA BIPERIDEN MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 138. SOUTH AFRICA BIPERIDEN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 139. SOUTH AFRICA BIPERIDEN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 140. SOUTH AFRICA BIPERIDEN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 141. SOUTH AFRICA BIPERIDEN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 142. SOUTH AFRICA BIPERIDEN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 143. DENMARK BIPERIDEN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 144. DENMARK BIPERIDEN MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 145. DENMARK BIPERIDEN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 146. DENMARK BIPERIDEN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 147. DENMARK BIPERIDEN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 148. DENMARK BIPERIDEN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 149. DENMARK BIPERIDEN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 150. NETHERLANDS BIPERIDEN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 151. NETHERLANDS BIPERIDEN MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 152. NETHERLANDS BIPERIDEN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 153. NETHERLANDS BIPERIDEN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 154. NETHERLANDS BIPERIDEN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 155. NETHERLANDS BIPERIDEN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 156. NETHERLANDS BIPERIDEN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 157. QATAR BIPERIDEN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 158. QATAR BIPERIDEN MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 159. QATAR BIPERIDEN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 160. QATAR BIPERIDEN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 161. QATAR BIPERIDEN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 162. QATAR BIPERIDEN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 163. QATAR BIPERIDEN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 164. FINLAND BIPERIDEN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 165. FINLAND BIPERIDEN MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 166. FINLAND BIPERIDEN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 167. FINLAND BIPERIDEN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 168. FINLAND BIPERIDEN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 169. FINLAND BIPERIDEN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 170. FINLAND BIPERIDEN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 171. SWEDEN BIPERIDEN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 172. SWEDEN BIPERIDEN MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 173. SWEDEN BIPERIDEN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 174. SWEDEN BIPERIDEN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 175. SWEDEN BIPERIDEN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 176. SWEDEN BIPERIDEN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 177. SWEDEN BIPERIDEN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 178. NIGERIA BIPERIDEN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 179. NIGERIA BIPERIDEN MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 180. NIGERIA BIPERIDEN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 181. NIGERIA BIPERIDEN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 182. NIGERIA BIPERIDEN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 183. NIGERIA BIPERIDEN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 184. NIGERIA BIPERIDEN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 185. EGYPT BIPERIDEN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 186. EGYPT BIPERIDEN MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 187. EGYPT BIPERIDEN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 188. EGYPT BIPERIDEN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 189. EGYPT BIPERIDEN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 190. EGYPT BIPERIDEN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 191. EGYPT BIPERIDEN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 192. TURKEY BIPERIDEN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 193. TURKEY BIPERIDEN MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 194. TURKEY BIPERIDEN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 195. TURKEY BIPERIDEN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 196. TURKEY BIPERIDEN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 197. TURKEY BIPERIDEN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 198. TURKEY BIPERIDEN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 199. ISRAEL BIPERIDEN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 200. ISRAEL BIPERIDEN MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 201. ISRAEL BIPERIDEN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 202. ISRAEL BIPERIDEN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 203. ISRAEL BIPERIDEN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 204. ISRAEL BIPERIDEN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 205. ISRAEL BIPERIDEN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 206. NORWAY BIPERIDEN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 207. NORWAY BIPERIDEN MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 208. NORWAY BIPERIDEN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 209. NORWAY BIPERIDEN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 210. NORWAY BIPERIDEN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 211. NORWAY BIPERIDEN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 212. NORWAY BIPERIDEN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 213. POLAND BIPERIDEN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 214. POLAND BIPERIDEN MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 215. POLAND BIPERIDEN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 216. POLAND BIPERIDEN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 217. POLAND BIPERIDEN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 218. POLAND BIPERIDEN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 219. POLAND BIPERIDEN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 220. SWITZERLAND BIPERIDEN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 221. SWITZERLAND BIPERIDEN MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 222. SWITZERLAND BIPERIDEN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 223. SWITZERLAND BIPERIDEN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 224. SWITZERLAND BIPERIDEN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 225. SWITZERLAND BIPERIDEN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 226. SWITZERLAND BIPERIDEN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 227. ASIA-PACIFIC BIPERIDEN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 228. ASIA-PACIFIC BIPERIDEN MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 229. ASIA-PACIFIC BIPERIDEN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 230. ASIA-PACIFIC BIPERIDEN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 231. ASIA-PACIFIC BIPERIDEN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 232. ASIA-PACIFIC BIPERIDEN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 233. ASIA-PACIFIC BIPERIDEN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 234. ASIA-PACIFIC BIPERIDEN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 235. CHINA BIPERIDEN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 236. CHINA BIPERIDEN MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 237. CHINA BIPERIDEN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 238. CHINA BIPERIDEN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 239. CHINA BIPERIDEN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 240. CHINA BIPERIDEN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 241. CHINA BIPERIDEN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 242. INDIA BIPERIDEN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 243. INDIA BIPERIDEN MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 244. INDIA BIPERIDEN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 245. INDIA BIPERIDEN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 246. INDIA BIPERIDEN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 247. INDIA BIPERIDEN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 248. INDIA BIPERIDEN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 249. JAPAN BIPERIDEN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 250. JAPAN BIPERIDEN MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 251. JAPAN BIPERIDEN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 252. JAPAN BIPERIDEN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 253. JAPAN BIPERIDEN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 254. JAPAN BIPERIDEN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 255. JAPAN BIPERIDEN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 256. AUSTRALIA BIPERIDEN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 257. AUSTRALIA BIPERIDEN MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 258. AUSTRALIA BIPERIDEN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 259. AUSTRALIA BIPERIDEN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 260. AUSTRALIA BIPERIDEN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 261. AUSTRALIA BIPERIDEN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 262. AUSTRALIA BIPERIDEN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 263. SOUTH KOREA BIPERIDEN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 264. SOUTH KOREA BIPERIDEN MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 265. SOUTH KOREA BIPERIDEN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 266. SOUTH KOREA BIPERIDEN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 267. SOUTH KOREA BIPERIDEN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 268. SOUTH KOREA BIPERIDEN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 269. SOUTH KOREA BIPERIDEN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 270. INDONESIA BIPERIDEN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 271. INDONESIA BIPERIDEN MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 272. INDONESIA BIPERIDEN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 273. INDONESIA BIPERIDEN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 274. INDONESIA BIPERIDEN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 275. INDONESIA BIPERIDEN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 276. INDONESIA BIPERIDEN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 277. THAILAND BIPERIDEN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 278. THAILAND BIPERIDEN MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 279. THAILAND BIPERIDEN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 280. THAILAND BIPERIDEN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 281. THAILAND BIPERIDEN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 282. THAILAND BIPERIDEN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 283. THAILAND BIPERIDEN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 284. PHILIPPINES BIPERIDEN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 285. PHILIPPINES BIPERIDEN MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 286. PHILIPPINES BIPERIDEN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 287. PHILIPPINES BIPERIDEN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 288. PHILIPPINES BIPERIDEN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 289. PHILIPPINES BIPERIDEN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 290. PHILIPPINES BIPERIDEN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 291. MALAYSIA BIPERIDEN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 292. MALAYSIA BIPERIDEN MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 293. MALAYSIA BIPERIDEN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 294. MALAYSIA BIPERIDEN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 295. MALAYSIA BIPERIDEN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 296. MALAYSIA BIPERIDEN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 297. MALAYSIA BIPERIDEN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 298. SINGAPORE BIPERIDEN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 299. SINGAPORE BIPERIDEN MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 300. SINGAPORE BIPERIDEN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 301. SINGAPORE BIPERIDEN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 302. SINGAPORE BIPERIDEN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 303. SINGAPORE BIPERIDEN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 304. SINGAPORE BIPERIDEN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 305. VIETNAM BIPERIDEN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 306. VIETNAM BIPERIDEN MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 307. VIETNAM BIPERIDEN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 308. VIETNAM BIPERIDEN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 309. VIETNAM BIPERIDEN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 310. VIETNAM BIPERIDEN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 311. VIETNAM BIPERIDEN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 312. TAIWAN BIPERIDEN MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 313. TAIWAN BIPERIDEN MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 314. TAIWAN BIPERIDEN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 315. TAIWAN BIPERIDEN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 316. TAIWAN BIPERIDEN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 317. TAIWAN BIPERIDEN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 318. TAIWAN BIPERIDEN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 319. BIPERIDEN MARKET SHARE, BY KEY PLAYER, 2024
TABLE 320. BIPERIDEN MARKET, FPNV POSITIONING MATRIX, 2024

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Biperiden market report include:
  • Teva Pharmaceutical Industries Ltd.
  • Sandoz International GmbH
  • Viatris Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Lupin Limited
  • Janssen-Cilag International NV
  • Aurobindo Pharma Limited
  • Apotex Inc.
  • Glenmark Pharmaceuticals Limited

Table Information

Report AttributeDetails
No. of Pages188
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 407.1 Million
Forecasted Market Value ( USD ) by 2030 $ 537.08 Million
Compound Annual Growth Rate5.7%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Biperiden Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Biperiden Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 71 Pages
  • Global
From
Biperiden (CAS 514-65-8) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029 - Product Image

Biperiden (CAS 514-65-8) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029

  • Report
  • 50 Pages
  • Global
From
Biperiden Hydrochloride (CAS 1235-82-1) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029 - Product Image

Biperiden Hydrochloride (CAS 1235-82-1) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029

  • Report
  • 50 Pages
  • Global
From
Muscarinic Acetylcholine Receptor M1 Antagonists- Pipeline Insight, 2025 - Product Image

Muscarinic Acetylcholine Receptor M1 Antagonists- Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From

About the Biperiden Market

Biperiden is a centrally acting anticholinergic drug used to treat a variety of conditions related to the central nervous system. It is used to treat Parkinson's disease, dystonia, and drug-induced extrapyramidal reactions. It is also used to treat symptoms of Alzheimer's disease, such as memory loss, confusion, and agitation. Biperiden is also used to treat symptoms of schizophrenia, such as hallucinations, delusions, and disorganized thinking. Biperiden is available in both oral and injectable forms. It is typically taken orally in the form of tablets or capsules, and is also available as an intramuscular injection. The injectable form is used to treat severe cases of Parkinson's disease and dystonia. Biperiden is a widely used drug in the central nervous system drug market. It is used to treat a variety of conditions, and is available in both oral and injectable forms. Some companies in the Biperiden market include Pfizer, Novartis, Merck, and Sanofi. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.